NetraMark, an AI technology company, has been hired by global CRO Worldwide Clinical Trials to find patient subpopulations concealed inside intricate data sets.

NetraMark's NetraAI is going to be implemented by Worldwide in phase 2 neuroscience and cancer trials as well as some phase 3 trials as part of the partnership. NetraMark stated in a statement on April 3 that the objective is to identify the most effective patient groups to test medicines on in order to ensure that studies proceed as smoothly and effectively as possible. According to the statement, NetraMark's technology will eventually be made available to all trial stages and a variety of therapeutic areas across Worldwide's global network of sponsors.

Global Chief Operating Officer Dave Bowser said that by incorporating NetraMark's technology into their clinical trial design, they can determine which patients are most likely to produce favorable trial outcomes. This will reduce the number of patients needed for each trial, cut down on time and expenses, and eventually boost success rates for their sponsors.

According to the announcement, using NetraAI enables Worldwide to improve trial power overall, decrease variability in placebo responses, improve patient stratification, and speed up development. The Ontario Brain Institute and Toronto-based NetraMark have collaborated to create analytical tools that expedite the processing of brain imagery, such as MRI scans.

According to the press announcement, Worldwide, as the name suggests, employs over 3,500 people in more than 60 countries. Jason Meggs, an industry veteran, was recently appointed chief financial officer in December 2024 by the CRO, shaking up its C-suite.